Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018

  • ID: 4592440
  • Drug Pipelines
  • 24 pages
  • Global Markets Direct
1 of 5
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape.

Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

Report Highlights:

This latest pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Report Coverage

Elephantiasis (Lymphatic Filariasis) - Overview

Elephantiasis (Lymphatic Filariasis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development

AbbVie Inc

Ebelle Pharmaceuticals Inc

Eisai Co Ltd

Elephantiasis (Lymphatic Filariasis) - Drug Profiles

AbbV-4083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDE-1206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filariasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lymphatic filariasis (multivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Lymphatic Filariasis and Onchocerciasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Elephantiasis (Lymphatic Filariasis) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Elephantiasis (Lymphatic Filariasis) - Pipeline by AbbVie Inc, H2 2018

Elephantiasis (Lymphatic Filariasis) - Pipeline by Ebelle Pharmaceuticals Inc, H2 2018

Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co Ltd, H2 2018

Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Ebelle Pharmaceuticals Inc
  • Eisai Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll